These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7592187)

  • 1. Are all carbapenems created equal?
    Baxter IA; Lambert PA
    J Antimicrob Chemother; 1995 May; 35(5):708-9. PubMed ID: 7592187
    [No Abstract]   [Full Text] [Related]  

  • 2. Are all carbapenems created equal?
    Iaconis JP; Nadler HL; Pitkin DH; Sheikh W
    J Antimicrob Chemother; 1994 Sep; 34(3):443-4. PubMed ID: 7530243
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all carbapenems created equal?
    Simpson IN; Hunter R; Govan JR
    J Antimicrob Chemother; 1995 May; 35(5):707-8. PubMed ID: 7592186
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of pH and CO2 on in vitro susceptibility of Pseudomonas cepacia to beta-lactams.
    Corkill JE; Deveney J; Pratt J; Shears P; Smyth A; Heaf D; Hart CA
    Pediatr Res; 1994 Mar; 35(3):299-302. PubMed ID: 7514780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and partial purification of a carbapenem-hydrolysing metallo-beta-lactamase from Pseudomonas cepacia.
    Baxter IA; Lambert PA
    FEMS Microbiol Lett; 1994 Oct; 122(3):251-6. PubMed ID: 7527361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temocillin and cystic fibrosis: outcome of intravenous administration in patients infected with Pseudomonas cepacia.
    Taylor RF; Gaya H; Hodson ME
    J Antimicrob Chemother; 1992 Mar; 29(3):341-4. PubMed ID: 1375595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nosocomially acquired Pseudomonas cepacia infection in patients with cystic fibrosis.
    Tablan OC
    Infect Control Hosp Epidemiol; 1993 Mar; 14(3):124-6. PubMed ID: 7683030
    [No Abstract]   [Full Text] [Related]  

  • 9. Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.
    Mustafa MH; Chalhoub H; Denis O; Deplano A; Vergison A; Rodriguez-Villalobos H; Tunney MM; Elborn JS; Kahl BC; Traore H; Vanderbist F; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6735-6741. PubMed ID: 27572406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β-lactamase-producing clone with a heterogeneous carbapenem resistance phenotype.
    Pollini S; Fiscarelli E; Mugnaioli C; Di Pilato V; Ricciotti G; Neri AS; Rossolini GM
    Clin Microbiol Infect; 2011 Aug; 17(8):1272-5. PubMed ID: 21375657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas cepacia--more than a harmless commensal?
    Lancet; 1992 Jun; 339(8806):1385-6. PubMed ID: 1375968
    [No Abstract]   [Full Text] [Related]  

  • 12. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis.
    Simpson IN; Finlay J; Winstanley DJ; Dewhurst N; Nelson JW; Butler SL; Govan JR
    J Antimicrob Chemother; 1994 Sep; 34(3):353-61. PubMed ID: 7530242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
    Zobell JT; Kemper AL; Young DC
    Pediatr Pulmonol; 2014 Mar; 49(3):E48-51. PubMed ID: 23661625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of phenotypic screening tests for carbapenemase production in Pseudomonas aeruginosa from patients with cystic fibrosis.
    Tai AS; Sidjabat HE; Kidd TJ; Whiley DM; Paterson DL; Bell SC
    J Microbiol Methods; 2015 Apr; 111():105-7. PubMed ID: 25680305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.
    Manno G; Ugolotti E; Belli ML; Fenu ML; Romano L; Cruciani M
    Eur J Clin Microbiol Infect Dis; 2003 Jan; 22(1):28-34. PubMed ID: 12582741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular methods require for confirmation in bla AIM (Adelaide imipenemase) producing Pseudomonas aeruginosa.
    Banerjee P; Singh G
    Burns; 2014 Nov; 40(7):1419. PubMed ID: 24969111
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to: Molecular methods require for confirmation blaAIM (Adelaide imipenemase) producing Pseudomonas aeruginosa.
    Jabalameli F; Kalantar-Neyestanaki D; Asadollahi K; Taherikalani M; Emaneini M
    Burns; 2014 Nov; 40(7):1419-20. PubMed ID: 24969112
    [No Abstract]   [Full Text] [Related]  

  • 19. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
    Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia.
    Egan JJ; McNeil K; Bookless B; Gould K; Corris P; Higenbottam T; Webb AK; Woodcock AA
    Lancet; 1994 Aug; 344(8921):552-3. PubMed ID: 7520109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.